ArticleRadiation oncology (London, England)2025
Potentially radiation-induced late toxicity after irradiation of pituitary adenoma, a retrospective dosimetric study.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults - a retrospective, single institute experience.Journal of neuro-oncology · 2026Article
- Gamma knife radiosurgery vs fractionated radiotherapy : gender difference in efficacy and toxicity.Pituitary · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is considered as a second or third-line treatment for recurrent pituitary adenomas. As it is a benign tumor, the balance should clearly favor the benefit and induce the least amount of side effects. PURPOSE: This retrospective study aims to evaluate the incidence of side effects after treatment and their actual causality with radiotherapy through dosimetric analysis.
methodsA cohort of 35 patients who underwent normofractionated radiation therapy following unsuccessful surgical or medical interventions was identified. 48.6% (17/35) had functioning adenomas (29.41% adrenocorticotrophic hormone-secreting, 35.3% growth hormone-secreting, and 23.5% prolactin-secreting adenomas). Surgery was previously employed in 94.29% of patients. A median dose of 54 Gy was prescribed in the planning target volume (PTV) in a normofractionated schedule. Patients were clinically monitored by endocrinologists, ophthalmologists, and radiation oncologists, and patients underwent MRI and hormonal analyses frequently.
resultsThe median follow-up time was 54.94 months. None of the patients experienced acute side effects of grade 3 or higher. Regarding late side effects, new-onset hypopituitarism was observed in 14.3% of patients, with all patients exceeding the dose constraint to pituitary gland. Additionally, 25.7% reported subjective memory loss complaints, 4 underwent a neuropsychological assessment, and only 2 were confirmed. Furthermore, 8 out of 9 patients did not adhere to the maximum dose constraints for the hippocampus. Subjective auditory impairment was experienced by 31.3% of patients, with 4 out of 11 undergoing ENT evaluation, and 1 out of 4 describing radio-induced tubal catharsis. All 11 patients adhered to the cochlear constraints. Five cases of cataracts were reported, with all patients adhering to lens constraints, although they were significantly older than those without cataracts. Two cases of temporary cranial nerve deficits, one visual impairment, one epilepsy, and one transient ischemic attack were also documented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.